Choosing the Right PSMA PET Tracer: Real-World Implications

With multiple PSMA PET tracers available, Jaideep S. Sohi, MD, shares insights about the benefits of the various options and his real-world experience with their use in practice.

EP: 1.Evolution of PSMA PET-CT Imaging in Patients With Prostate Cancer

EP: 2.Revolutionizing Prostate Cancer Imaging with PSMA PET-CT

EP: 3.The Evolution of Prostate Cancer Imaging: Embracing the Power of PSMA PET/CT

EP: 4.The Role of PSMA PET/CT Imaging in Diagnosing and Staging Prostate Cancer in Practice

EP: 5.Advancing Patient Care Through Precision PSMA PET/CT Imaging

EP: 6.PSMA PET/CT Imaging Utility in Real-World Practices

EP: 7.The Impact of PSMA PET/CT Imaging on Managing Prostate Cancer

Now Viewing

EP: 8.Choosing the Right PSMA PET Tracer: Real-World Implications

EP: 9.PSMA PET-CT Imaging: Impact on Real-World Diagnosis and Management of Prostate Cancer

Related Videos

Related Content

Advertisement

February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor

In both racial cohorts, median MFS was not reached in the darolutamide group.

Related Content

Advertisement

February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor

In both racial cohorts, median MFS was not reached in the darolutamide group.